Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | TDO2 | P48775 | 1/20 | 0.42 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
| ▸ | ERN1 | O75460 | 1/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 7/20 | 0.39 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.39 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.39 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30610188 | 1.00 | IDO1 (0.42) | IDO1TDO2CCNA2CDK2ERN1 | |
| SCHEMBL17731756 | 0.89 | IDO1 (0.41) | IDO1TDO2CCNA2CDK2TRPV1 | |
| SCHEMBL31687246 | 0.85 | JAK1 (0.43) | IDO1TDO2CCNA2CDK2TRPV1 | |
| SCHEMBL29092528 | 0.83 | METAP2 (0.47) | IDO1TDO2CDK2TRPV1 | |
| SCHEMBL30602751 | 0.83 | METAP2 (0.47) | IDO1TDO2CDK2TRPV1 | |
| SCHEMBL17739283 | 0.79 | SMO (0.42) | IDO1TDO2ERN1 | |
| SCHEMBL28459521 | 0.77 | IDO1 (0.38) | IDO1TDO2CCNA2CDK2TRPV1 | |
| SCHEMBL17739098 | 0.77 | FASN (0.42) | IDO1TDO2TRPV1 | |
| SCHEMBL17731753 | 0.77 | METAP2 (0.42) | IDO1TDO2CDK2TRPV1 | |
| SCHEMBL17738576 | 0.76 | JAK2 (0.51) | IDO1TDO2TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3215156-B1 | INHIBITORS OF TRYPTOPHAN-2,3-DIOXYGENASE OR INDOLEAMINE-2,3-DIOXYGENASE | IOMET PHARMA LTD (GB) | 2025-09-24 | — | — | EP | disclosed |
| CN-111943890-B | Pharmaceutical compounds | 艾欧米制药有限公司 | 2023-10-31 | — | — | CN | disclosed |
| US-11130738-B2 | Pharmaceutical compound | IOMET PHARMA LTD. (GB) | 2021-09-28 | — | — | US | disclosed |
| US-11130738-B2 | Pharmaceutical compound | IOMET PHARMA LTD. (GB) | 2021-09-28 | — | — | US | disclosed |
| CN-111943890-A | Pharmaceutical compounds | 艾欧米制药有限公司 | 2020-11-17 | — | — | CN | disclosed |
| CN-107108556-B | Pharmaceutical compounds | 艾欧米制药有限公司 | 2020-09-29 | — | — | CN | disclosed |
| US-20200172492-A1 | PHARMACEUTICAL COMPOUND | IOMET PHARMA LTD. (GB) | 2020-06-04 | — | — | US | disclosed |
| US-20200172492-A1 | PHARMACEUTICAL COMPOUND | IOMET PHARMA LTD. (GB) | 2020-06-04 | — | — | US | disclosed |
| US-10590086-B2 | Pharmaceutical compound | IOMET PHARMA LTD. (GB) | 2020-03-17 | — | — | US | disclosed |
| US-10590086-B2 | Pharmaceutical compound | IOMET PHARMA LTD. (GB) | 2020-03-17 | — | — | US | disclosed |
| US-20180354908-A1 | PHARMACEUTICAL COMPOUND | IOMET PHARMA LTD. (GB) | 2018-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11130738-B2 | Pharmaceutical compound | IDO1, TDO2, IDO2 | IDO1 1/4885TDO2 2/4885CCNA2 2517/4885 |
| US-20200172492-A1 | PHARMACEUTICAL COMPOUND | IDO1, TDO2, IDO2 | IDO1 1/4885TDO2 2/4885CCNA2 2517/4885 |
| US-10590086-B2 | Pharmaceutical compound | IDO1, TDO2, IDO2 | IDO1 1/4885TDO2 2/4885CCNA2 2517/4885 |
| US-20180354908-A1 | PHARMACEUTICAL COMPOUND | IDO1, TDO2, IDO2 | IDO1 1/4885TDO2 2/4885CCNA2 2517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.